Trial · NCT04885530
ACTIV-6: COVID-19 Study of Repurposed Medications
NCT04885530, Phase 3, Completed, Susanna Naggie, MD; results first posted 2025-11-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ACTIV-6: COVID-19 Study of Repurposed Medications. Trials, record NCT04885530. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04885530
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ACTIV-6: COVID-19 Study of Repurposed Medications
- NCT number
- NCT04885530
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 10,956 participants, actual
- Lead sponsor
- Susanna Naggie, MD
- Conditions
- Covid19
- Interventions
- Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
- First posted
- 2021-05-13
- Last updated
- 2025-11-17
- Results first posted
- 2025-11-17
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Number of Participants Randomized Within Each Appendix | Up to approximately 2 years 10 months | Total number of participants randomized within each Appendix will be reported. Appendix-specific outcome measure data will be reported under the associated NCT ID. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Number of Participants Randomized Within Each Appendix | Up to approximately 2 years 10 months | Individuals who met inclusion criteria and consented for study drug for each study arm. Given that participants were not randomized at this point, one number is reported for each study arm as a whole. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Number of Participants Randomized Within Each Appendix | Arm A - Ivermectin 400 | 1800 | Participants | ||
| Total Number of Participants Randomized Within Each Appendix | Arm B - Fluvoxamine | 1331 | Participants | ||
| Total Number of Participants Randomized Within Each Appendix | Arm C - Fluticasone | 1407 | Participants | ||
| Total Number of Participants Randomized Within Each Appendix | Arm D - Ivermectin 600 | 1459 | Participants | ||
| Total Number of Participants Randomized Within Each Appendix | Arm E - Fluvoxamine 100 | 1208 | Participants | ||
| Total Number of Participants Randomized Within Each Appendix | Arm F - Montelukast | 1453 | Participants | ||
| Total Number of Participants Randomized Within Each Appendix | Arm G - Metformin | 3214 | Participants |
Source ClinicalTrials.gov
Participant flow147
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Substudy A | STARTED | Arm A - Ivermectin 400 | 1,800 | |
| Substudy A | STARTED | Arm B - Fluvoxamine | 0 | |
| Substudy A | STARTED | Arm C - Fluticasone | 0 | |
| Substudy A | STARTED | Arm D - Ivermectin 600 | 0 | |
| Substudy A | STARTED | Arm E - Fluvoxamine 100 | 0 | |
| Substudy A | STARTED | Arm F - Montelukast | 0 | |
| Substudy A | STARTED | Arm G - Metformin | 0 | |
| Substudy A | COMPLETED | Arm A - Ivermectin 400 | 1,800 | |
| Substudy A | COMPLETED | Arm B - Fluvoxamine | 0 | |
| Substudy A | COMPLETED | Arm C - Fluticasone | 0 |
1 to 10 of 147Source ClinicalTrials.gov
See all 147 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals21
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A - Ivermectin 400 | 0 | 1,800 |
| Total, all-cause mortality | Arm B - Fluvoxamine | 0 | 1,331 |
| Total, all-cause mortality | Arm C - Fluticasone | 0 | 1,407 |
| Total, all-cause mortality | Arm D - Ivermectin 600 | 0 | 1,459 |
| Total, all-cause mortality | Arm E - Fluvoxamine 100 | 0 | 1,208 |
| Total, all-cause mortality | Arm F - Montelukast | 0 | 1,453 |
| Total, all-cause mortality | Arm G - Metformin | 0 | 3,214 |
| Total, other adverse events | Arm A - Ivermectin 400 | 0 | 1,800 |
| Total, other adverse events | Arm B - Fluvoxamine | 0 | 1,331 |
| Total, other adverse events | Arm C - Fluticasone | 0 | 1,407 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 adverse event totalsPapers15
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U24TR001608 | Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT) | BENJAMIN, DANIEL K. | DUKE UNIVERSITY | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2016 to 2022 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04885530
GET https://conductscience.org/api/trials/v1/NCT04885530/flow?page=2